文献速递泌尿男性生殖肿瘤

哪些转移性激素敏感性前列腺癌患者可从多西他赛获益:随机试验个体参与者数据的系统综述与Meta分析

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
PubMed 文献 · Lancet Oncol · 2023-01-01

该研究通过系统综述与Meta分析个体参与者数据,评估多西他赛联合雄激素剥夺治疗(ADT)对转移性激素敏感性前列腺癌的疗效,并分析患者特征对疗效的影响。结果显示多西他赛显著改善总生存(HR 0.79,95%CI 0.70-0.88)、无进展生存(HR 0.70)和无失败生存(HR 0.64),5年绝对改善约9-11%。高肿瘤负荷和临床T4期患者绝对获益最大,低体积异时性转移患者无显著获益。

要点

  • 多西他赛联合ADT显著改善转移性激素敏感性前列腺癌的总生存(HR 0.79)、无进展生存(HR 0.70)和无失败生存(HR 0.64)。
  • 临床T分期越高、转移体积越大,多西他赛对无进展生存的相对效应越强。
  • 高体积且临床T4期患者5年绝对获益最大(无进展生存27%,总生存35%)。

核心结论

  • 多西他赛联合激素治疗最适合基于高疾病体积和潜在原发肿瘤 bulky 的预后较差的转移性激素敏感性前列腺癌患者。
  • 对于异时性、低体积疾病患者,没有证据表明有意义的获益,因此应进行不同的管理。

研究设计与样本

  • STOPCAP M1协作组进行的系统综述与个体参与者数据Meta分析,检索MEDLINE、Embase、Cochrane Central Register of Controlled Trials(均从数据库建库至2022年3月31日)、相关会议论文集(1990年1月1日至2022年12月31日)和ClinicalTrials.gov(从建库至2023年3月28日)。
  • 纳入评估多西他赛联合ADT对比单用ADT的 eligible 随机试验,获得3项试验(GETUG-AFU15、CHAARTED和STAMPEDE)2261例患者(占随机化患者的98%)的个体参与者数据,中位随访72个月(IQR 55-85)。
  • 主要终点为总生存,次要终点为无进展生存和无失败生存;采用调整的意向性治疗两阶段固定效应Meta分析,并进行一阶段和随机效应敏感性分析。

主要发现

  • 多西他赛对总生存的获益明确(HR 0.79,95%CI 0.70-0.88;p<0.0001),无进展生存(HR 0.70,95%CI 0.63-0.77;p<0.0001),无失败生存(HR 0.64,95%CI 0.58-0.71;p<0.0001),5年绝对改善约9-11%。
  • 多西他赛对无进展生存的相对效应随临床T分期增加(交互作用p=0.0019)、转移体积增大(交互作用p=0.020)而增大,异时性诊断的交互作用较弱(p=0.077)。
  • 考虑其他交互作用后,多西他赛的效应独立受体积和临床T分期修饰,而不受时机修饰。
  • 低体积、异时性疾病患者5年绝对获益无显著改善:无进展生存-1%(95%CI -15至12),总生存0%(95%CI -10至12)。
  • 高体积、临床T4期患者5年绝对获益最大:无进展生存27%(95%CI 17至37),总生存35%(95%CI 24至47)。

关键数值与推荐

  • 总生存HR 0.79(95%CI 0.70-0.88;p<0.0001),无进展生存HR 0.70(95%CI 0.63-0.77;p<0.0001),无失败生存HR 0.64(95%CI 0.58-0.71;p<0.0001)。
  • 无进展生存交互作用:临床T分期p=0.0019,转移体积p=0.020,异时性诊断p=0.077。
  • 高体积、临床T4期5年绝对改善:无进展生存27%(95%CI 17至37),总生存35%(95%CI 24至47)。
  • 低体积、异时性5年绝对改善:无进展生存-1%(95%CI -15至12),总生存0%(95%CI -10至12)。

临床怎么用

  • 多西他赛联合激素治疗最适合基于高疾病体积和潜在原发肿瘤 bulky 的预后较差的转移性激素敏感性前列腺癌患者。
  • 对于异时性、低体积疾病患者,没有证据表明有意义的获益,因此应进行不同的管理。

局限性

  • 未从另外两项小型试验获得个体参与者数据。
  • 低体积、异时性疾病的5年绝对效应置信区间宽(无进展生存95%CI -15至12,总生存95%CI -10至12)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adding docetaxel to androgen deprivation therapy (ADT) improves survival in patients with metastatic, hormone-sensitive prostate cancer, but uncertainty remains about who benefits most. We therefore aimed to obtain up-to-date estimates of the overall effects of docetaxel and to assess whether these effects varied according to prespecified characteristics of the patients or their tumours. METHODS: The STOPCAP M1 collaboration conducted a systematic review and meta-analysis of individual participant data. We searched MEDLINE (from database inception to March 31, 2022), Embase (from database inception to March 31, 2022), the Cochrane Central Register of Controlled Trials (from database inception to March 31, 2022), proceedings of relevant conferences (from Jan 1, 1990, to Dec 31, 2022), and ClinicalTrials.gov (from database inception to March 28, 2023) to identify eligible randomised trials that assessed docetaxel plus ADT compared with ADT alone in patients with metastatic, hormone-sensitive prostate cancer. Detailed and updated individual participant data were requested directly from study investigators or through relevant repositories. The primary outcome was overall survival. Secondary outcomes were progression-free survival and failure-free survival. Overall pooled effects were estimated using an adjusted, intention-to-treat, two-stage, fixed-effect meta-analysis, with one-stage and random-effects sensitivity analyses. Missing covariate values were imputed. Differences in effect by participant characteristics were estimated using adjusted two-stage, fixed-effect meta-analysis of within-trial interactions on the basis of progression-free survival to maximise power. Identified effect modifiers were also assessed on the basis of overall survival. To explore multiple subgroup interactions and derive subgroup-specific absolute treatment effects we used one-stage flexible parametric modelling and regression standardisation. We assessed the risk of bias using the Cochrane Risk of Bias 2 tool. This study is registered with PROSPERO, CRD42019140591. FINDINGS: We obtained individual participant data from 2261 patients (98% of those randomised) from three eligible trials (GETUG-AFU15, CHAARTED, and STAMPEDE trials), with a median follow-up of 72 months (IQR 55-85). Individual participant data were not obtained from two additional small trials. Based on all included trials and patients, there were clear benefits of docetaxel on overall survival (hazard ratio [HR] 0·79, 95% CI 0·70 to 0·88; p<0·0001), progression-free survival (0·70, 0·63 to 0·77; p<0·0001), and failure-free survival (0·64, 0·58 to 0·71; p<0·0001), representing 5-year absolute improvements of around 9-11%. The overall risk of bias was assessed to be low, and there was no strong evidence of differences in effect between trials for all three main outcomes. The relative effect of docetaxel on progression-free survival appeared to be greater with increasing clinical T stage (pinteraction=0·0019), higher volume of metastases (pinteraction=0·020), and, to a lesser extent, synchronous diagnosis of metastatic disease (pinteraction=0·077). Taking into account the other interactions, the effect of docetaxel was independently modified by volume and clinical T stage, but not timing. There was no strong evidence that docetaxel improved absolute effects at 5 years for patients with low-volume, metachronous disease (-1%, 95% CI -15 to 12, for progression-free survival; 0%, -10 to 12, for overall survival). The largest absolute improvement at 5 years was observed for those with high-volume, clinical T stage 4 disease (27%, 95% CI 17 to 37, for progression-free survival; 35%, 24 to 47, for overall survival). INTERPRETATION: The addition of docetaxel to hormone therapy is best suited to patients with poorer prognosis for metastatic, hormone-sensitive prostate cancer based on a high volume of disease and potentially the bulkiness of the primary tumour. There is no evidence of meaningful benefit for patients with metachronous, low-volume disease who should therefore be managed differently. These results will better characterise patients most and, importantly, least likely to gain benefit from docetaxel, potentially changing international practice, guiding clinical decision making, better informing treatment policy, and improving patient outcomes. FUNDING: UK Medical Research Council and Prostate Cancer UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Vale CL, Fisher DJ, Godolphin PJ, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023. PMID: 37414011. doi:10.1016/S1470-2045(23)00230-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。